FDA Launches System To Track Performances of Its Offices
This article was originally published in The Tan Sheet
Executive Summary
For those wondering how many adverse events reports FDA received last month, the number of Risk Evaluation and Mitigation Strategies it cleared or the number of first generics it approved, the answers are now readily accessible
You may also be interested in...
FDA Congressional Relations, Internal Structure May Change With Sharfstein Exit
The departure of Principal Deputy Commissioner Josh Sharfstein provides FDA an opportunity to take stock of its relationship with Congress and to re-evaluate its organizational structure.
FDA Congressional Relations, Internal Structure May Change With Sharfstein Exit
The departure of Principal Deputy Commissioner Josh Sharfstein provides FDA an opportunity to take stock of its relationship with Congress and to re-evaluate its organizational structure.
FDA Congressional Relations, Internal Structure May Change With Sharfstein Exit
The departure of Principal Deputy Commissioner Josh Sharfstein provides FDA an opportunity to take stock of its relationship with Congress and to re-evaluate its organizational structure.